|
 
 |
| LETTER TO EDITOR |
|
| Year : 2019 | Volume
: 33
| Issue : 2 | Page : 116 |
|
Cost–utility analysis of toxoplasmosis serological screening: Comparison between application in pregnant and HIV-infected patients
Beuy Joob1, Viroj Wiwanitkit2
1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Community Medicine, Dr DY Patil University, Pune, Maharashtra, India
| Date of Submission | 18-Aug-2018 |
| Date of Acceptance | 04-Aug-2019 |
| Date of Web Publication | 11-Feb-2020 |
Correspondence Address:
Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jms.jms_48_18
How to cite this article:
Joob B, Wiwanitkit V. Cost–utility analysis of toxoplasmosis serological screening: Comparison between application in pregnant and HIV-infected patients. J Med Soc 2019;33:116 |
How to cite this URL:
Joob B, Wiwanitkit V. Cost–utility analysis of toxoplasmosis serological screening: Comparison between application in pregnant and HIV-infected patients. J Med Soc [serial online] 2019 [cited 2023 Jun 5];33:116. Available from: https://www.jmedsoc.org/text.asp?2019/33/2/116/278101 |
Sir,
Toxoplasmosis is an important parasitic infestation. The disease is still prevalent in several tropical developing countries. The disease is considered an important problem in pregnant women because it can result in congenital disorder in offspring of infected pregnant women.[1] In addition, toxoplasmosis is also considered an important infectious disease seen in the immunocompromised host such as HIV-infected patients.[2] Serological screening for toxoplasmosis is widely used for screening purpose of the risk groups. Here, the authors report the cost–utility analysis of toxoplasmosis serological screening based on data from an endemic area of disease, southern region of Thailand. For cost–utility analysis, the cost is referred to the referencing cost provided by the Thai Ministry of Public Health and presented in USD. Hereby, the utility is assigned as detection rate of screening. Focusing on utility, the data from the same setting in Songkhla province, south of Thailand, published in the available reports, are used.[3],[4] According to this study, the cost of serological screening test is equal to 9 USD, and the utility for screening for pregnant women and HIV-infected cases is equal to 25% and 36.3%, respectively. The cost per utility for screening for pregnant women and HIV-infected cases is equal to 36 and 24.79 USD/detection, respectively. According to this study, the cost utility is more for using serological screening for toxoplasmosis among HIV-infected patients.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | |  |
| 1. | Paquet C, Yudin MH; Society of Obstetricians and Gynaecologists of Canada. Toxoplasmosis in pregnancy: Prevention, screening, and treatment. J Obstet Gynaecol Can 2013;35:78-81.  |
| 2. | Machala L, Kodym P, Malý M, Geleneky M, Beran O, Jilich D. Toxoplasmosis in immunocompromised patients. Epidemiol Mikrobiol Imunol 2015;64:59-65. |
| 3. | Chemoh W, Sawangjaroen N, Siripaitoon P, Andiappan H, Hortiwakul T, Sermwittayawong N, et al. Toxoplasma gondii – Prevalence and risk factors in HIV-infected patients from Songklanagarind Hospital, Southern Thailand. Front Microbiol 2015;6:1304. |
| 4. | Andiappan H, Nissapatorn V, Sawangjaroen N, Chemoh W, Lau YL, Kumar T, et al. Toxoplasma infection in pregnant women: A current status in Songklanagarind hospital, Southern Thailand. Parasit Vectors 2014;7:239. |
|
Search Pubmed for